Pizotifen (BC-105): a review of its pharmacological properties and its therapeutic efficacy in vascular headaches.
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002986:Clinical Trials as Topic; D003508:Cycloheptanes / Q000627:therapeutic use* / Q000633:toxicity; D003533:Cyproheptadine / Q000627:therapeutic use; D004285:Dogs; D004873:Ergolines / Q000627:therapeutic use; D006168:Guinea Pigs; D000882:Haplorhini; D006261:Headache / Q000188:drug therapy*; D006634:Histamine H1 Antagonists / Q000494:pharmacology; D006801:Humans; D006993:Hypnotics and Sedatives / Q000494:pharmacology; D007928:Lethal Dose 50; D008784:Methysergide / Q000627:therapeutic use; D051379:Mice; D008881:Migraine Disorders / Q000188:drug therapy*; D010640:Phenothiazines / Q000627:therapeutic use; D010880:Piperidines / Q000627:therapeutic use / Q000633:toxicity; D011817:Rabbits; D051381:Rats; D012702:Serotonin Antagonists; D013876:Thiophenes / Q000627:therapeutic use* / Q000633:toxicity; D014653:Vascular Headaches / Q000188:drug therapy
D003508:Cycloheptanes; D004873:Ergolines; D006634:Histamine H1 Antagonists; D006993:Hypnotics and Sedatives; D010640:Phenothiazines; D010880:Piperidines; D012702:Serotonin Antagonists; D013876:Thiophenes; D003533:Cyproheptadine; D008784:Methysergide